WAVE Life Sciences prices IPO at $16, raises $102M
November 13, 2015
WAVE Life Sciences, a preclinical biopharma developing nucleic acid therapeutics, has raised a total of $102 million through its IPO. Listed on the NASDAQ under the symbol WVE, the company offered about 6.4 million shares at $16 each. Proceeds from the offering will be used to fund multiple preclinical and clinical trials for several drug candidates. WAVE last raised a $66 million financing in August; shareholders include RA Capital Management (35.8% pre-IPO stake), Foresite Capital Management (9.2%) and Fidelity Management and Research (8.3%).